PHARMACEUTICAL COMPOSITION CONTAINING AN ANIONIC DRUG, AND A METHOD FOR PRODUCTION THEREOF Russian patent published in 2020 - IPC A61K9/107 A61K31/7105 A61K31/711 A61K47/34 A61K47/50 

FIELD: pharmaceutical industry.

SUBSTANCE: group of inventions relates to an anionic drug delivery composition comprising: an anionic drug; cationic compound, selected from polyethyleneimine and cationic lipid of formula 7 (, where n and m = 0–12 under condition 2≤n+m≤12, a and b=1–6, R₁ and R₂ are selected from saturated and unsaturated C_11-25 hydrocarbons); amphiphilic two-block block-copolymer of type AB, consisting of hydrophilic block A selected from monomethoxy polyethylene glycol and polyalkylene glycol, and hydrophobic block B, which is a polyester; and at least one compound of formula 1 (RO-CHZ-[A]_n-[B]_m-COOM, where A -COO-CHZ-; B -COO-CHY-; R is a hydrogen atom, acetyl, benzoyl, decanoyl, palmitoyl, methyl or ethyl; Z and Y are methyl; M is Na, K or Li; n=1–30, m=0–20 with the condition n+m=7–50) and formula 6 (YO-[-C(O)-(CHX)_a-O-]_m-C(O)-R-C(O)-[-O-(CHX')_b-C(O)-]_n-OZ, where X and X' are methyl; Y and Z—Na, K or Li; m and n are integer from 0 to 95 under condition 5<m+n<100; a and b = 1; R -(CH₂)_k- with the proviso k=2). Anionic drug and cationic compound by electrostatic interaction form complex, which is enclosed in micellar structure of block-copolymer and compound of formula 1 and/or 6.

EFFECT: group of inventions provides improved stability of an anionic drug in blood or body fluid.

22 cl, 2 dwg, 18 tbl, 32 ex